Internal Medicine · Longview, TX
NPI
1215255179
Since 2010
Specialty
Internal Medicine
Code 207R00000X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
703 E Marshall Ave Ste 5008
Longview, TX, 75601
Phone (903) 315-5555
Groups this clinician bills Medicare through
Medicare paid, 2024
$71K
1,066 services
Medicare patients, 2024
315
Average age 73
Drug cost, 2024
$129K
526 prescriptions
Company payments, 2025
$23.33
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Suganya Manivannan was code 99232 (hospital e&m - subsequent), 416 times for 181 patients. In total Suganya Manivannan billed 1,066 services in 14 codes, and Medicare paid $71K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-08-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 416 | 181 | $64.30 | $27K |
| 99231 Hospital E&M - Subsequent | Facility | 279 | 153 | $40.04 | $11K |
| 99222 Hospital E&M - Initial | Facility | 221 | 199 | $105.25 | $23K |
| 99213 Office E&M - Established | Facility | 42 | 23 | $51.56 | $2,166 |
| 99212 Office E&M - Established | Facility | 32 | 28 | $27.26 | $872 |
| 99221 Hospital E&M - Initial | Facility | 29 | 29 | $67.39 | $1,954 |
| 99214 Office E&M - Established | Facility | 20 | 17 | $80.04 | $1,601 |
By year: 2022 $32K for 276 services; 2023 $36K for 578 services; 2024 $71K for 1,066 services.
Medicare prescription drug claims, 2024
In 2024, the drug Suganya Manivannan prescribed most often to Medicare patients was Daptomycin, with 81 prescriptions and refills. In total Suganya Manivannan wrote 526 Medicare prescriptions that cost $129K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Daptomycin Generic | 81 | 81 | 21 | $49K |
| Ertapenem Ertapenem Sodium | 78 | 78 | 22 | $26K |
| Vancomycin Hcl Generic | 72 | 72 | 19 | $7,759 |
| Ceftriaxone Ceftriaxone Sodium | 41 | 41 | Under 11 | $2,654 |
| Sodium Chloride 0.9 % Sodium Chloride | 30 | 30 | Under 11 | $139 |
| Oxacillin Sodium Generic | 21 | 21 | Under 11 | $13K |
| Ceftazidime Generic | 17 | 17 | Under 11 | $2,370 |
| Micafungin Micafungin Sodium | 17 | 17 | Under 11 | $3,102 |
| Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav | 14 | 14 | 14 | $183 |
| Ampicillin-Sulbactam Ampicillin Sod/Sulbactam Sod | 14 | 14 | Under 11 | $3,323 |
| Doxycycline Hyclate Generic | 14 | 16 | 12 | $205 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 11 | 11 | Under 11 | $74.22 |
Brand drugs: 84 claims; generic drugs: 442 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Suganya Manivannan $23.33 ($23.33 in general payments such as food, travel and fees) from 1 company. The largest payer was Abbvie Inc. with $23.33.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 1 | $23.33 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.